Liquid Biopsy Testing

Now offering mobile phlebotomy services

NeoGenomics offers a broad collection of comprehensive, targeted and single gene liquid biopsy assays for solid tumor cancer and hematologic malignancies. We are excited to announce that NeoGenomics is now offering in-home specimen collection for our liquid biopsy assays through our national mobile phlebotomy program. Our goal is to provide all patients access to testing in a timely manner to ensure efficient diagnosis and disease progression monitoring.


A ctDNA NGS liquid biopsy testing 37 genes relevant to the care of advanced NSCLC patients.

NeoLAB® Solid Tumor Liquid Biopsy

Rapid, high-quality NGS-based genomic profile for pan-cancer.

NeoLAB® Heme Liquid Biopsy

Detection of critical biomarkers in patients with known and suspected hematologic cancers.

National  Mobile Phlebotomy Program

Safe and convenient in-home blood draws with no added cost for patients

For more information contact
NeoGenomics Client Services at 1-866-776-5907.
Download the mobile phlebotomy brochure

“This in-home service addresses patient fears of exposure to COVID-19, and ensures the efficient continuity of care, which is so crucial in the treatment and monitoring of cancer patients.”

- Douglas VanOort, CEO

Learn how to access our new National Mobile Phlebotomy Service for blood-based tests, to ensure no delays in care for cancer patients.

Questions about...
Liquid Biopsy
Cancer Testing
Precision Medicine
Tissue vs Plasma
Liquid Biopsy refers to the analysis of blood by whole cancer cells (CTCs) or components of cells such as circulating tumor DNA (ctDNA) in order to characterize solid tumors. During the cancer lifecycle, DNA from our cancer cells break down and shed into the bloodstream, called circulating tumor DNA (ctDNA). From a simple blood draw, liquid biopsy testing can be performed to detect specific genetic variations in the ctDNA of a patient’s blood sample that may be causing the cancer to grow.
Liquid biopsy testing is a novel approach to genomic profiling and has shown to offer several advantages over tissue biopsy for select clinical scenarios. In the case of limited or insufficient tumor tissue or when a repeat biopsy is required for treatment monitoring, liquid biopsy may be a good option for patients largely because it is a minimally invasive procedure. Additionally, the location of the tumor may be difficult or even dangerous to contact for biopsy and testing of ctDNA by a blood draw might be a suitable alternative to traditional tissue biopsy. Lastly, liquid biopsy testing accounts for potential tumor evolution and heterogeneity since the ctDNA comes from cells anywhere in the body, whereas tissue biopsy is a sample taken from an isolated tumor.

Liquid biopsy testing helps inform precision decisions by the following:

  • Inform treatment strategies
  • Monitor disease progression
  • Evaluate therapeutic effectiveness



Tissue Biopsy

High diagnostic certainty

Lack of representativeness of tumor heterogeneity

Liquid Biopsy

Can detect tumor heterogeneity

Cannot detect location of tumor mutations

Representative analysis of multiple tumor foci

No diagnostic value if no mutation detected

PIK3CA Mutation CDx Sponsored Testing Program

Available with liquid biopsy testing

PIK3CA Mutation CDx in Tissue or Plasma is a new biomarker-driven strategy for the detection of the PIK3CA mutation and identification of eligible patients for appropriate therapy.

*InVisionFirst®-Lung is a trademark of Inivata Limited.